| Patent application number | Description | Published |
|---|
| 20090253976 | Intracardiac Tracking System - In general, in one aspect, a method is disclosed for determining information about a position of an object. The method includes: (i) causing current to flow between each of three or more sets of current-injecting electrodes on a first catheter inserted into an organ in a patient's body, the organ having a periphery (ii) in response to current flow caused by each set of current injecting electrodes, measuring an electrical signal at each of one or more measuring electrodes located on one or more additional catheters inserted into the organ in the patient's body and (iii) determining the position of each of one or more of the measuring electrodes on the additional catheters relative to the first catheter based on the measured signals from the one or more measuring electrodes. | 10-08-2009 |
| 20100274150 | Multi-Electrode Mapping System - In some aspects, a method includes measuring unipolar signals at one or more electrodes in response to electrical activity in a heart cavity. The method also includes determining, based at least in part on Laplace's equation, bipolar physiological information at multiple locations of an surface based on the measured unipolar signals and positions of the one or more electrodes with respect to the surface. | 10-28-2010 |
| 20100286550 | Impedance Based Anatomy Generation - Methods and systems for the determination and representation of anatomy anatomical information are disclosed herein. | 11-11-2010 |
| 20100286551 | Impedance Based Anatomy Generation - Methods and systems for the determination and representation of anatomy anatomical information are disclosed herein. | 11-11-2010 |
| 20110275949 | MULTI-ELECTRODE MAPPING SYSTEM - In some aspects, a method includes measuring unipolar signals at one or more electrodes in response to electrical activity in a heart cavity. The method also includes determining, based at least in part on Laplace's equation, bipolar physiological information at multiple locations of an surface based on the measured unipolar signals and positions of the one or more electrodes with respect to the surface. | 11-10-2011 |
| 20120130267 | IMPEDANCE BASED ANATOMY GENERATION - Methods and systems for the determination and representation of a chamber anatomy are disclosed herein. | 05-24-2012 |
| 20120253161 | IMPEDANCE BASED ANATOMY GENERATION - Methods and systems for the determination and representation of anatomy anatomical information are disclosed herein. | 10-04-2012 |
| 20120277567 | INTRA-CARDIAC TRACKING SYSTEM - In general, in one aspect, a method is disclosed for determining information about a position of an object. The method includes: (i) causing current to flow between each of three or more sets of current-injecting electrodes on a first catheter inserted into an organ in a patient's body, the organ having a periphery (ii) in response to current flow caused by each set of current injecting electrodes, measuring an electrical signal at each of one or more measuring electrodes located on one or more additional catheters inserted into the organ in the patient's body and (iii) determining the position of each of one or more of the measuring electrodes on the additional catheters relative to the first catheter based on the measured signals from the one or more measuring electrodes. | 11-01-2012 |
| 20130345538 | Intracardiac Tracking System - In general, in one aspect, a method is disclosed for determining information about a position of an object. The method includes: (i) causing current to flow between each of three or more sets of current-injecting electrodes on a first catheter inserted into an organ in a patient's body, the organ having a periphery (ii) in response to current flow caused by each set of current injecting electrodes, measuring an electrical signal at each of one or more measuring electrodes located on one or more additional catheters inserted into the organ in the patient's body and (iii) determining the position of each of one or more of the measuring electrodes on the additional catheters relative to the first catheter based on the measured signals from the one or more measuring electrodes. | 12-26-2013 |
| 20140200442 | Intracardiac Tracking System - In general, in one aspect, a method is disclosed for determining information about a position of an object. The method includes: (i) causing current to flow between each of three or more sets of current-injecting electrodes on a first catheter inserted into an organ in a patient's body, the organ having a periphery (ii) in response to current flow caused by each set of current injecting electrodes, measuring an electrical signal at each of one or more measuring electrodes located on one or more additional catheters inserted into the organ in the patient's body and (iii) determining the position of each of one or more of the measuring electrodes on the additional catheters relative to the first catheter based on the measured signals from the one or more measuring electrodes. | 07-17-2014 |
| 20140235986 | IMPEDANCE BASED ANATOMY GENERATION - Methods and systems for the determination and representation of anatomy anatomical information are disclosed herein. | 08-21-2014 |
| 20150223726 | INTRACARDIAC TRACKING SYSTEM - In general, in one aspect, a method is disclosed for determining information about a position of an object. The method includes: (i) causing current to flow between each of three or more sets of current-injecting electrodes on a first catheter inserted into an organ in a patient's body, the organ having a periphery (ii) in response to current flow caused by each set of current injecting electrodes, measuring an electrical signal at each of one or more measuring electrodes located on one or more additional catheters inserted into the organ in the patient's body and (iii) determining the position of each of one or more of the measuring electrodes on the additional catheters relative to the first catheter based on the measured signals from the one or more measuring electrodes. | 08-13-2015 |
| Patent application number | Description | Published |
|---|
| 20120289717 | NEW PROCESS FOR THE PREPARATION OF DRONEDARONE - The subject of the present invention is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide of formula I: | 11-15-2012 |
| 20130261321 | PROCESS FOR THE PREPARATION OF DRONEDARONE - The subject of the present invention is a novel process for the preparation of N-[2-n-butyl-3-{4-[(3-dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide of formula I: | 10-03-2013 |
| 20140114081 | PROCESS FOR PREPARATION OF DRONEDARONE BY N-BUTYLATION - The invention relates to a novel process for preparation of dronedarone (I) and pharmaceutically acceptable salts thereof where the compound of formula (II) or salt thereof is reacted with a compound of formula L-(CH | 04-24-2014 |
| 20150031902 | PROCESS FOR THE PREPARATION OF DRONEDARONE BY OXIDATION OF A SULPHENYL GROUP - The invention relates to a novel process for the preparation of dronedarone (I) and pharmaceutically acceptable salts thereof which comprises oxidizing a compound of formula (IV) or a salt thereof with an oxidizing agent in an organic or inorganic solvent or solvent mixture, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. Further aspects of the invention include the novel intermediary compound of formula (IV), and a process for the preparation thereof. | 01-29-2015 |
| 20150274688 | PROCESS FOR PREPARATION OF DRONEDARONE BY GRIGNARD REACTION - The invention relates to a novel process for the preparation of dronedarone (I) and pharmaceutically acceptable salts thereof, which comprises reacting of compound of formula (IV) with compound of formula (VI) in a Grignard reaction, and the obtained product is isolated and, if desired, converted into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and processes for the preparation thereof. | 10-01-2015 |
| Patent application number | Description | Published |
|---|
| 20140365647 | Network Visualization Systems And Methods - Example network visualization systems and methods are described. In one implementation, a method displays a network environment as a network graph using a first zoom level. The method receives a request to provide a second zoom level in a particular portion of the network environment. Network components are identified to display at the second zoom level in the particular portion of the network environment. The method further determines which network connections to display at the second zoom level in the particular portion of the network environment and generates a revised network graph containing the identified network components and the determined network connections. | 12-11-2014 |
| 20140365648 | Network Management Systems and Methods - Example network management systems and methods are described. In one implementation, a method identifies at least one network resource to be managed and identifies at least one domain to be managed. The method further identifies at least one service provider to be managed. A fusion object is created that defines the network resource, the domain, and the service provider to be managed. | 12-11-2014 |
| 20150113452 | GRAPHICAL USER INTERFACE - A graphical user interface system for a computer system is disclosed. Regions of interest and locations thereof are defined. Icons are associated with the regions and the sizing and arrangement thereof is determined according to rules, such as user-specified rules. A representation of the icons of a region may be enhanced or altered in response to user interaction. An altered representation may animate icons of a region, enlarge an icon, augment information displayed on an icon, or perform other functions. | 04-23-2015 |
| Patent application number | Description | Published |
|---|
| 20100220587 | SYSTEM AND METHOD PROVIDING OVERLOAD CONTROL IN NEXT GENERATION NETWORKS - A system, method and node for overload control in a network. The method includes the steps of receiving an incoming offer by a node, filtering the offer by an in-throttle to determine if the offer is permitted to be processed by the node prior to processing by the node, processing a permitted offer, and sending the processed offer to a designated target. After processing the permitted offer by the node, the offer may be further filtered prior to sending the offer to the designated target. | 09-02-2010 |
| 20110093592 | IMS PERFORMANCE MONITORING - A method and apparatus enabling performance monitoring in packet-switched IP networks such as those configured according to an IP multimedia subsystem, IMS, architecture. Performance is monitored by reconstructing selected control signaling sequences. The control signaling sequences, which are typically executed according a signaling protocol such as the Session Initiation Protocol, SIP, are reconstructed by parsing the contents of monitoring request headers configured, modified, and attached to control messages according to the present invention. The header includes at least an IMS monitoring ID field ( | 04-21-2011 |
| 20110182176 | METHOD AND APPARATUS TO PROVIDE MINIMUM RESOURCE SHARING WITHOUT BUFFERING REQUESTS - A throttle device is coupled with a central processing unit in a node for reducing traffic overload in a Next Generation Network (NGN). The device is coupled with a basic throttle with different levels of traffic priority and both are situated between a source node and a target node for processing traffic. When a traffic offer is received by the throttle, the throttle device by provisionally updating the basic throttle priority levels, determines whether to send the traffic offer on to the source node. If the provisional, traffic priority level is greater than a new traffic priority level the traffic is admitted and rejected if the updated priority level is less than the new traffic priority level. | 07-28-2011 |
| 20110202593 | FOCUSED SAMPLING OF TERMINAL REPORTS IN A WIRELESS COMMUNICATION NETWORK - A performance management system and method are described herein that can control which client terminal(s) (e.g., mobile terminal(s)) are to provide Quality of Experience, QoE, report(s) and also control a level of detail for the requested QoE report(s). | 08-18-2011 |
| 20130272197 | Technique for Introducing a Real-Time Congestion Status in a Policy Decision for a Cellular Network - A technique for introducing a real-time congestion status in a Policy and Charging Rules Function (PCRF) policy decision in a cellular network is presented. A method embodiment performed by the PCRF comprises the steps of obtaining, from one of a Policy Charging Enforcement Function (PCEF) and a database, at least one cell identifier; sending, to a Performance Manager network element, a request for checking congestion status, the request comprising the at least one cell identifier; receiving, from the Performance Manager network element, a retrieved congestion status for the at least one cell identifier; generating at least one of a QoS Class Identifier and a QoS Profile based on the at least one cell identifier and the received congestion status; and sending, to the PCEF, a message comprising the at least one of the Class Identifier and QoS Profile. | 10-17-2013 |
| 20130294263 | Method and Device for Monitoring Wireless Terminal Behavior According to Terminal Type - One or more embodiments of a method and device taught herein provide for monitoring wireless terminal behavior in a wireless communication network, where each wireless terminal has a defined terminal type. Data describing the behavior of a plurality of wireless terminals in the wireless communication network is obtained. Based on the obtained data, an aggregated severity score for a given terminal type is determined that is indicative of the extent to which one or more of a plurality of performance criteria have not been met by wireless terminals of the given terminal type. If the aggregated severity score for the given terminal type exceeds a corresponding severity score threshold, one or more of a plurality of predefined actions are performed based on the extent to which the threshold is exceeded. | 11-07-2013 |
| 20140330960 | Systems and Methods for Identifying Applications in Mobile Networks - A method for identifying an application installed in a user device of a communication system is disclosed. Based on user device and network resources utilized by the user device and installation information about applications installed application, an identification of an application can be performed. An advantage with embodiments of this invention is that an application can be identified, without prior information how the application affects user device and network resources. Malicious and noxious applications can thereby be identified. Also, a resource consumption reporting service offered to the subscribers by the operator is enabled. | 11-06-2014 |
| Patent application number | Description | Published |
|---|
| 20080248657 | Method and system for thermally processing a plurality of wafer-shaped objects - Process and system for processing wafer-shaped objects, such as semiconductor wafers is disclosed. In accordance with the present disclosure, a multiple of two wafers are processed in a thermal processing chamber. The thermal processing chamber is in communication with at least one heating device for heating the wafers. The wafers are placed in the thermal processing chamber in a face-to-face configuration or in a back-to-back configuration. | 10-09-2008 |
| 20080311761 | Method for the Thermal Treatment of Disk-Shaped Substrates - Disclosed is an apparatus and a method for reducing flash in an injection mold ( | 12-18-2008 |
| 20090242543 | Monitoring Witness Structures for Temperature Control in RTP Systems - Temperature control in an RTP system can be improved by consideration of one or more witness structures different from the wafer (or other semiconductor object) being processed. For example, power coupling between the RTP heating system and witness structure can be used to adjust one or more control parameters, such as model definitions, that are used by the RTP system to control wafer heating. As another example, a stored trajectory of a desired witness structure temperature or other property can be used as a basis for control during a processing cycle. Thus, the witness structure may be controlled “closed-loop” while the wafer is heated “open-loop.” As a further example, a heat flux between the RTP heating system and witness structure can be used to determine radiant energy from the heating system that is incident on the witness structure. One or more control actions can be taken based on this incident energy. | 10-01-2009 |
| 20100151694 | METHOD AND APPARATUS FOR GROWING THIN OXIDE FILMS ON SILICON WHILE MINIMIZING IMPACT ON EXISTING STRUCTURES - Plasma assisted low temperature radical oxidation is described. The oxidation is selective to metals or metal oxides that may be present in addition to the silicon being oxidized. Selectivity is achieved by proper selection of process parameters, mainly the ratio of H2 to O2 gas. The process window may be enlarged by injecting H2O steam into the plasma, thereby enabling oxidation of silicon in the presence of TiN and W, at relatively low temperatures. Selective oxidation is improved by the use of an apparatus having remote plasma and flowing radicals onto the substrate, but blocking ions from reaching the substrate. | 06-17-2010 |
| 20120298039 | METHOD AND APPARATUS FOR GROWING THIN OXIDE FILMS ON SILICON WHILE MINIMIZING IMPACT ON EXISTING STRUCTURES - Plasma assisted low temperature radical oxidation is described. The oxidation is selective to metals or metal oxides that may be present in addition to the silicon being oxidized. Selectivity is achieved by proper selection of process parameters, mainly the ratio of H2 to O2 gas. The process window may be enlarged by injecting H2O steam into the plasma, thereby enabling oxidation of silicon in the presence of TiN and W, at relatively low temperatures. Selective oxidation is improved by the use of an apparatus having remote plasma and flowing radicals onto the substrate, but blocking ions from reaching the substrate. | 11-29-2012 |
| Patent application number | Description | Published |
|---|
| 20110104043 | INSTRUMENT AND PROCESS FOR NANOPARTICLES PRODUCTION IN CONTINUOUS FLOW MODE - The subject of the invention is the ( | 05-05-2011 |
| 20130202706 | NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. | 08-08-2013 |
| 20130209521 | NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. | 08-15-2013 |
| 20130210794 | NANOSTRUCTURED EZETIMIBE COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average particle size of less than about 400 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance compared to the marketed drug. Ezetimibe is an anti-hyperlipidemic medication that is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine. | 08-15-2013 |
| 20150132388 | COMPLEXES OF FULVESTRANT AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to pharmaceutically acceptable complex formulae comprising complexes of Fulvestrant, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present invention have improved physicochemical properties which makes the compound orally available and makes oral administration of the compound possible in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. | 05-14-2015 |
| Patent application number | Description | Published |
|---|
| 20120141561 | NANOPARTICULATE CANDESARTAN CILEXITIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist. | 06-07-2012 |
| 20120148637 | NANOPARTICULATE OLMESARTAN MEDOXOMIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc. | 06-14-2012 |
| Patent application number | Description | Published |
|---|
| 20110104043 | INSTRUMENT AND PROCESS FOR NANOPARTICLES PRODUCTION IN CONTINUOUS FLOW MODE - The subject of the invention is the ( | 05-05-2011 |
| 20120128740 | NANOSTRUCTURED SILDENAFIL BASE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND CO-CRYSTALS, COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average particle size of less than about 500 nm. Sildenafil citrate is inhibiting cGMP specific phosphodiesterase type 5 (PDEV), an enzyme that regulates blood flow in the penis. The compositions of the invention are useful in the treatment of male or female sexual dysfunction and pulmonary arterial hypertension (PAH). | 05-24-2012 |
| 20120135053 | NANOPARTICULATE TELMISARTAN COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF - The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. | 05-31-2012 |
| 20130202706 | NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. | 08-08-2013 |
| 20130209521 | NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. | 08-15-2013 |
| 20130210794 | NANOSTRUCTURED EZETIMIBE COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average particle size of less than about 400 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance compared to the marketed drug. Ezetimibe is an anti-hyperlipidemic medication that is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine. | 08-15-2013 |
| Patent application number | Description | Published |
|---|
| 20090314553 | Retractable electronic pen with sensing arrangement - An electronic pen comprises a retractable cartridge, a retraction mechanism for extending and retracting the cartridge, a button for actuating the retraction mechanism, a sensing arrangement for sensing a configuration of the pen, and a processor cooperating with the sensing arrangement. The processor is adapted to configure a state of the pen in response to input signals from the sensing arrangement. The sensing arrangement comprises a button sensor coupled to the button, which senses actuation of the button and a cartridge sensor for sensing whether the cartridge is extended or retracted. | 12-24-2009 |
| 20090315734 | Electronic pen with automatically retractable nib - An electronic pen for interacting with a surface. The pen comprises a retractable cartridge having a nib, an automatic retraction mechanism for automatically retracting the cartridge, and a processor for controlling the automatic retraction mechanism. The processor is configured to automatically retract the cartridge in response to predetermined pen conditions. | 12-24-2009 |
| 20090315862 | ELECTRONIC PEN WITH RETRACTABLE NIB AND FORCE SENSOR - An electronic pen having a retractable nib for interacting with a surface. The pen comprises a slidably movable cartridge having a nib for contacting the surface, a retraction mechanism for retracting the cartridge, an actuator coupled to the retraction mechanism, a force sensor providing a reaction to an axial force transmitted from the cartridge, and a processor configured for generating force data indicative of a force detected by the force sensor. The retraction mechanism comprises a barrel for receiving the cartridge, which is adapted for seating the cartridge in either an extended position or a retracted position, whereby the axial force from the cartridge is transmitted to the barrel in the extended position. A biasing mechanism biases the cartridge towards the extended or retracted positions. | 12-24-2009 |
| 20090315863 | ELECTRONIC PEN HAVING FAST RESPONSE TIME - An electronic pen for interacting with a surface. The pen comprises a cartridge having a nib for contacting the surface, a capacitive force sensor cooperating with said cartridge for sensing a nib force transmitted axially through the cartridge, and a processor configured to generate force data indicative of a force detected by the force sensor. The capacitive force sensor comprises: a spring having an integral conductive moving plate resiliently biased towards a reference position, a conductive fixed plate and a dielectric separating said plates. | 12-24-2009 |
| 20090315864 | Electronic pen with retractable and replaceable cartridge - An electronic pen comprises a user-replaceable cartridge having a nib, a force sensor for sensing a nib force transmitted axially through the cartridge from the nib and a retraction mechanism for retracting the cartridge. The retraction mechanism comprises a barrel adapted for seating the cartridge in either an extended position or a retracted position, and a first biasing mechanism for biasing the cartridge towards the extended or retracted positions. A second biasing mechanism biases the barrel towards engagement with the force sensor. | 12-24-2009 |
| 20100079602 | METHOD AND APPARATUS FOR ALIGNMENT OF AN OPTICAL ASSEMBLY WITH AN IMAGE SENSOR - A method is described for positioning an image sensor at a point of best focus for a lens. The lens has an optical axis and the image sensor is moved to a plurality of positions along the optical axis. The image sensor captures an image of a target image at each of the plurality of positions through the lens. A measure of blur in the image captured is derived at each of the plurality of positions from pixel data output from the image sensor. A relationship is derived between blur and position of the image sensor along the optical axis. The image sensor is then moved to a position on the optical axis that the relationship indicates as the point of best focus where the image sensor is fixedly secured relative to the lens. | 04-01-2010 |
| Patent application number | Description | Published |
|---|
| 20100207177 | METHOD FOR PRODUCING A COPPER CONTACT - A method for producing a contact through the pre-metal dielectric (PMD) layer of an integrated circuit, between the front end of line and the back end of line, and the device produced thereby are disclosed. The PMD layer includes oxygen. In one aspect, the method includes producing a hole in the PMD, depositing a conductive barrier layer at the bottom of the hole, depositing a CuMn alloy on the bottom and side walls of the hole, filling the remaining portion of the hole with Cu. The method further includes performing an anneal process to form a barrier on the side walls of the hole, wherein the barrier has an oxide including Mn. The method further includes performing a CMP process. | 08-19-2010 |
| 20150130062 | Method for Manufacturing Germanide Interconnect Structures and Corresponding Interconnect Structures - Method for forming an interconnect structure, comprising the steps of: forming a recessed structure in a dielectric material on a substrate; at least partially filling said recessed structure with a metal chosen from the group consisting of copper, nickel and cobalt; introducing the substrate in a CVD reactor; bringing the substrate in the CVD reactor to a soak temperature and subsequently performing a soak treatment by supplying a germanium precursor gas to the CVD reactor at the soak temperature, thereby substantially completely converting the metal in the recessed structure to a germanide. | 05-14-2015 |
| 20150162913 | FILED PROGRAMMABLE GATE ARRAY DEVICE WITH PROGRAMMABLE INTERCONNECT IN BACK END OF LINE PORTION OF THE DEVICE - A Field-Programmable Gate Array device is provided with programmable interconnect points in the form of interconnect circuits comprising one or more pass transistors, wherein at least some components of the interconnect circuits are implemented in the Back-End-Of-Line part of the Field-Programmable Gate Array device's production process. The memory element in an interconnect point is not produced as a Static Random Access Memory cell, but as a Dynamic Random Access Memory cell, requiring only a single select transistor and a storage capacitor for each memory element. The fabrication of at least the select transistor and the pass transistor involves the use of a thin film semiconductor layer, e.g., Indium Gallium Zinc Oxide, enabling production of transistors with low leakage in the Back-End-Of-Line. | 06-11-2015 |
